The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells (CART-BCMA) are a promising treatment for relapsed/refractory multiple myeloma (r/rMM). We evaluated the safety and feasibility of bridging radiation (RT) in subjects treated on a phase I trial of CART-BCMA. Twenty-fiv...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2021-12, Vol.27 (23), p.6580-6590
Main Authors: Manjunath, Shwetha H, Cohen, Adam D, Lacey, Simon F, Davis, Megan M, Garfall, Alfred L, Melenhorst, J Joseph, Maxwell, Russell, Arscott, W Tristram, Maity, Amit, Jones, Joshua A, Plastaras, John P, Stadtmauer, Edward A, Levine, Bruce L, June, Carl H, Milone, Michael C, Paydar, Ima
Format: Article
Language:English
Subjects:
B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive - adverse effects
Multiple Myeloma - drug therapy
Receptors, Chimeric Antigen
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells (CART-BCMA) are a promising treatment for relapsed/refractory multiple myeloma (r/rMM). We evaluated the safety and feasibility of bridging radiation (RT) in subjects treated on a phase I trial of CART-BCMA. Twenty-five r/rMM subjects were treated in three cohorts with two doses of CART-BCMA cells ± cyclophosphamide. We retrospectively analyzed toxicity, response, and CART manufacturing data based on RT receipt. Thirteen subjects received no RT
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-21-0308